For Investors

Corporate Profile
AVEO Oncology is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates.
Stock Quote
AVEO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.21
Change (%) Stock is Up 0.02 (1.68%)
Volume500,179
Data as of 07/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press Releases 
DateTitle 
05/31/14AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--May 31, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results wer... 
Printer Friendly Version
05/28/14AVEO Oncology to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast will be a... 
Printer Friendly Version
05/07/14AVEO Oncology Reports First Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “We made solid progress executing on a key component of our recently announced corporate strategy, which is to advance our clinical-stage assets through collaborations while retaining substantial value,” said Tuan Ha-Ngoc, president a... 
Printer Friendly Version
More Press Releases >>
Upcoming Events 
There are currently no events scheduled.
More Events >>
Presentations 
Date
05/31/14
First in human Phase 1 dose-escalation study of AV-203; #395, J. Sarantopoulos
05/19/14
AACR 2014, Cancer Cachexia Poster #1441, Liu
12/10/13
7th Annual Cachexia Conference, GDF-15 oral presentation
04/10/13
AACR 2013, Cancer Cachexia poster - Abstract 4650, Vigano
04/09/13
AACR 2013, GDF-15 poster - Abstract 3504, Lerner
More Presentations >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.